Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.

Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH.

Ann Rheum Dis. 2019 Jul 30. pii: annrheumdis-2019-215764. doi: 10.1136/annrheumdis-2019-215764. [Epub ahead of print]

2.

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial.

Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC.

Arthritis Rheumatol. 2019 Jul 9. doi: 10.1002/art.41032. [Epub ahead of print]

PMID:
31287230
3.

Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target.

Legrand J, Kirchgesner T, Sokolova T, Vande Berg B, Durez P.

Joint Bone Spine. 2019 Mar 27. pii: S1297-319X(19)30052-1. doi: 10.1016/j.jbspin.2019.03.008. [Epub ahead of print]

PMID:
30928534
4.

Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, de Bellefon LM, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 19;20(1):282. doi: 10.1186/s13075-018-1795-5.

5.

Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, Meric de Bellefon L, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 3;20(1):265. doi: 10.1186/s13075-018-1762-1. Erratum in: Arthritis Res Ther. 2018 Dec 19;20(1):282.

6.

Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe.

Just SA, Humby F, Lindegaard H, Meric de Bellefon L, Durez P, Vieira-Sousa E, Teixeira R, Stoenoiu M, Werlinrud J, Rosmark S, Larsen PV, Pratt A, Choy E, Gendi N, Buch MH, Edwards CJ, Taylor PC, McInnes IB, Fonseca JE, Pitzalis C, Filer A.

RMD Open. 2018 Oct 26;4(2):e000799. doi: 10.1136/rmdopen-2018-000799. eCollection 2018.

7.

[Life-threatening hypercalcemia and acute kidney injury induced by etanercept].

Tsevi YM, Aydin S, Durez P, Labriola L.

Nephrol Ther. 2018 Nov;14(6):478-482. doi: 10.1016/j.nephro.2018.05.001. Epub 2018 Jun 29. French.

PMID:
30401463
8.

Fasciae of the musculoskeletal system: normal anatomy and MR patterns of involvement in autoimmune diseases.

Kirchgesner T, Demondion X, Stoenoiu M, Durez P, Nzeusseu Toukap A, Houssiau F, Galant C, Acid S, Lecouvet F, Malghem J, Vande Berg B.

Insights Imaging. 2018 Oct;9(5):761-771. doi: 10.1007/s13244-018-0650-1. Epub 2018 Aug 29. Review.

9.

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.

van der Heijde D, Durez P, Schett G, Naredo E, Østergaard M, Meszaros G, De Leonardis F, de la Torre I, López-Romero P, Schlichting D, Nantz E, Fleischmann R.

Clin Rheumatol. 2018 Sep;37(9):2381-2390. doi: 10.1007/s10067-018-4221-0. Epub 2018 Aug 4.

10.

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1.

PMID:
29752584
11.

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R.

J Rheumatol. 2018 Aug;45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15.

12.

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 May;37(5):1417-1420. doi: 10.1007/s10067-018-4074-6. Epub 2018 Apr 2. Erratum in: Clin Rheumatol. 2018 May 12;:.

PMID:
29611083
13.

Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review.

Combe B, Lula S, Boone C, Durez P.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):658-667. Epub 2018 Mar 20. Review.

14.

Switching of biologics in RA patients who do not respond to the first biologic.

Durez P.

Joint Bone Spine. 2018 Jul;85(4):395-397. doi: 10.1016/j.jbspin.2018.02.001. Epub 2018 Feb 13. No abstract available.

PMID:
29452302
15.

Severe panniculitis and polyarthritis caused by acinar cell carcinoma arising from an ectopic pancreas.

Plier M, Durez P, Komuta M, Raptis A.

BMJ Case Rep. 2017 Nov 21;2017. pii: bcr-2017-222241. doi: 10.1136/bcr-2017-222241.

PMID:
29167188
16.

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.

Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo WL, Won JE, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, Zerbini CAF.

Arthritis Res Ther. 2017 Sep 18;19(1):208. doi: 10.1186/s13075-017-1410-1.

17.

Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study.

Durez P, Vanthuyne M, Soyfoo MS, Hoffman I, Malaise M, Geusens P.

Acta Clin Belg. 2017 Dec;72(6):424-428. doi: 10.1080/17843286.2017.1314079. Epub 2017 Apr 21.

PMID:
28431485
18.

A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study.

De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P, Elewaut D; Be-Raise study group.

PLoS One. 2016 Nov 28;11(11):e0166607. doi: 10.1371/journal.pone.0166607. eCollection 2016.

19.

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.

Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbini CA, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P.

Rheumatology (Oxford). 2016 Aug;55(8):1466-76. doi: 10.1093/rheumatology/kew179. Epub 2016 Apr 25.

20.

Is There a Future for Interleukin 17 Blocking Agents in Rheumatoid Arthritis?

Durez P.

J Rheumatol. 2016 Mar;43(3):465-7. doi: 10.3899/jrheum.160010. No abstract available.

PMID:
26932985
21.

Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy.

De Groof A, Ducreux J, Humby F, Nzeusseu Toukap A, Badot V, Pitzalis C, Houssiau FA, Durez P, Lauwerys BR.

Arthritis Res Ther. 2016 Jan 20;18:19. doi: 10.1186/s13075-016-0919-z.

22.

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.

Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.

Arthritis Care Res (Hoboken). 2016 Jun;68(6):744-52. doi: 10.1002/acr.22759.

23.

Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.

Burmester GR, Durez P, Shestakova G, Genovese MC, Schulze-Koops H, Li Y, Wang YA, Lewitzky S, Koroleva I, Berneis AA, Lee DM, Hueber W.

Rheumatology (Oxford). 2016 Jan;55(1):49-55. doi: 10.1093/rheumatology/kev258. Epub 2015 Aug 12.

PMID:
26268815
24.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.

25.

Heterogeneity of synovial molecular patterns in patients with arthritis.

Lauwerys BR, Hernández-Lobato D, Gramme P, Ducreux J, Dessy A, Focant I, Ambroise J, Bearzatto B, Nzeusseu Toukap A, Van den Eynde BJ, Elewaut D, Gala JL, Durez P, Houssiau FA, Helleputte T, Dupont P.

PLoS One. 2015 Apr 30;10(4):e0122104. doi: 10.1371/journal.pone.0122104. eCollection 2015.

26.

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.

Westhovens R, Robles M, Ximenes AC, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Murthy B.

Ann Rheum Dis. 2015 Mar;74(3):564-8. doi: 10.1136/annrheumdis-2014-206149. Epub 2014 Dec 30.

27.

Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial.

Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T, Mociran E, Fautrel B, Mariette X, Dhellin O, Fanget B, Ouary S, Grouard-Vogel G, Boissier MC.

PLoS One. 2014 Dec 17;9(12):e113465. doi: 10.1371/journal.pone.0113465. eCollection 2014.

28.

Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire.

Wilburn J, McKenna SP, Twiss J, Rouse M, Korkosz M, Jancovic R, Nemec P, Pacheco-Tena CF, Saraux A, Westhovens R, Durez P, Martin M, Tammaru M.

Rheumatol Int. 2015 Apr;35(4):669-75. doi: 10.1007/s00296-014-3138-4. Epub 2014 Oct 1.

PMID:
25270915
29.

Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.

De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R; MIRA Study Group.

J Rheumatol. 2014 Sep;41(9):1761-5. doi: 10.3899/jrheum.131279. Epub 2014 Aug 15.

PMID:
25128506
30.

Ten-year followup of infliximab therapy in rheumatoid arthritis patients with severe, longstanding refractory disease: a cohort study.

De Keyser F, De Kock J, Leroi H, Durez P, Westhovens R; Infliximab EAP Study Group.

J Rheumatol. 2014 Jul;41(7):1276-81. doi: 10.3899/jrheum.131270. Epub 2014 Jun 1.

PMID:
24882838
31.

Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.

Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A, Schulze-Koops H, Durez P, Wolff V, Yao R, Weng HH, Govoni M, Vastesaeger N.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1799-807. doi: 10.1002/acr.22371.

32.

Predictive value of ACR core set parameters for the development of rheumatoid arthritis in patients with positive anti-cyclic citrullinated peptide antibodies and undifferentiated arthritis.

Meric de Bellefon L, Houssiau F, Depresseux G, Nzeusseu Toukap A, Lauwerys B, Durez P.

Rheumatology (Oxford). 2014 Jul;53(7):1347-8. doi: 10.1093/rheumatology/keu160. Epub 2014 May 8. No abstract available.

PMID:
24811973
33.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K.

Ann Rheum Dis. 2014 Sep;73(9):1607-15. doi: 10.1136/annrheumdis-2013-204760. Epub 2014 Mar 18.

34.

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R.

J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1.

35.

Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis.

Nzeusseu Toukap A, Delporte C, Noyon C, Franck T, Rousseau A, Serteyn D, Raes M, Vanhaeverbeek M, Moguilevsky N, Nève J, Vanhamme L, Durez P, Van Antwerpen P, Zouaoui Boudjeltia K.

Free Radic Res. 2014 Apr;48(4):461-5. doi: 10.3109/10715762.2014.886327. Epub 2014 Feb 20.

PMID:
24460011
36.

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.

Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.

Arthritis Rheumatol. 2014 Jan;66(1):15-23. doi: 10.1002/art.38202.

37.

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.

Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S.

J Rheumatol. 2014 Mar;41(3):414-21. doi: 10.3899/jrheum.130637. Epub 2014 Jan 15.

PMID:
24429175
38.

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.

Lancet. 2014 Jan 25;383(9914):321-32. doi: 10.1016/S0140-6736(13)61751-1. Epub 2013 Oct 26. Erratum in: Lancet. 2014 Jan 25;383(9914):308.

PMID:
24168956
40.

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.

Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH; GO-MORE Investigators.

Ann Rheum Dis. 2014 Aug;73(8):1477-86. doi: 10.1136/annrheumdis-2013-203229. Epub 2013 Jun 5.

41.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B.

Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17.

PMID:
23332236
42.

Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.

Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P.

Ann Rheum Dis. 2013 May;72(5):741-4. doi: 10.1136/annrheumdis-2012-202221. Epub 2012 Nov 17.

PMID:
23161899
43.

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.

Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, Catrina AI, DiCarlo J, Gaillez C, Le Bars M, Zhou X, Peterfy C.

Ann Rheum Dis. 2013 Aug;72(8):1287-94. doi: 10.1136/annrheumdis-2012-201611. Epub 2012 Aug 21.

44.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.

Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S.

Ann Rheum Dis. 2013 Jun;72(6):863-9. doi: 10.1136/annrheumdis-2012-201601. Epub 2012 Jun 23.

PMID:
22730366
45.

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Moniz Reed D, Helfrick R, Westhovens R.

Ann Rheum Dis. 2011 Nov;70(11):1949-56. doi: 10.1136/ard.2010.145268. Epub 2011 Aug 6.

PMID:
21821865
46.

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D; Treat to Target Taskforce.

Ann Rheum Dis. 2011 Nov;70(11):1999-2002. doi: 10.1136/ard.2011.154179. Epub 2011 Jul 29.

47.

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

Alten R, Gomez-Reino J, Durez P, Beaulieu A, Sebba A, Krammer G, Preiss R, Arulmani U, Widmer A, Gitton X, Kellner H.

BMC Musculoskelet Disord. 2011 Jul 7;12:153. doi: 10.1186/1471-2474-12-153.

48.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R.

Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463.

49.

The anti-CD20 antibody rituximab reduces the Th17 cell response.

van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA.

Arthritis Rheum. 2011 Jun;63(6):1507-16. doi: 10.1002/art.30314.

50.

Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative.

Hazlewood G, Aletaha D, Carmona L, Landewé RB, van der Heijde DM, Bijlsma JW, Bykerk VP, Canhão H, Catrina AI, Durez P, Edwards CJ, Leeb BF, Mjaavatten MD, Martinez-Osuna P, Montecucco C, Ostergaard M, Serra-Bonett N, Xavier RM, Zochling J, Machado P, Thevissen K, Vercoutere W, Bombardier C.

J Rheumatol Suppl. 2011 Mar;87:54-8. doi: 10.3899/jrheum.101076. Review.

PMID:
21364058

Supplemental Content

Support Center